Incubator Addition: Arix CIO On Why Fund Added VelosBio To Portfolio

 
• By Sten Stovall

Incubator fund Arix Bioscience has expanded its start-up portfolio to 15 by co-leading a series A financing for - and taking an equity stake in – antibody-drug conjugate specialist VelosBio. CIO Joe Anderson explains why.

Growth
VelosBio Now Readying For Launch Trials In cancer cell-targeting ADCs • Source: Shutterstock

More from Strategy

More from Business